Critical Care · 2008 · 31 citations · 24 references
MedicineHematologyPharmacotherapyCardiovascular PharmacotherapyInterventional CardiologyRenal Replacement TherapyAnticoagulant TherapyAnticoagulation TherapyAntiplatelet TherapyAntithrombotic TherapyPlatelet ActivationPlatelet TransfusionAnticoagulant PharmacologyAnticoagulation During Coronary InterventionAnticoagulation RegimenAntiplatelet DrugsPlatelet Aggregation InhibitionPlatelet ConsumptionPlatelet HemostasisRenal Replacement Therapy Anticoagulation
INTRODUCTION: Approximately one third of all patients with cardiogenic shock suffer from acute kidney injury. Percutaneous coronary intervention, intra-aortic balloon pump, and continuous renal replacement therapy (CRRT) require effective antiplatelet therapy and anticoagulation, resulting in a high risk for platelet loss and bleeding events. The reversible platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban was investigated to preserve platelet number and activation in a prospective open-blinded endpoint evaluation study. METHODS: Forty patients with cardiogenic shock and acute kidney injury requiring CRRT were randomly assigned to two groups receiving unfractioned heparin (UFH) (n = 20) or a combined anticoagulation with UFH and tirofiban (n = 20). The primary endpoint was platelet loss during CRRT. Secondary endpoints were urea reduction, haemofilter life span, bleeding events, and necessity for platelet transfusions. RESULTS: In UFH-treated patients, the percentage of platelet-monocyte aggregates significantly increased (P < 0.001) and consecutively platelet cell count significantly decreased (P < 0.001). In contrast, combined treatment with UFH and tirofiban significantly decreased platelet-monocyte aggregates and platelet numbers (P < 0.001). CONCLUSIONS: This pilot study provides evidence that the use of tirofiban in addition to UFH prevents platelet loss and preserves platelet function in patients with cardiogenic shock and acute kidney injury requiring CRRT. The pathophysiological inhibition of platelet aggregation and platelet-monocyte interaction appears to be causally involved.
24
One-Year Survival Following Early Revascularization for Cardiogenic Shock
Judith S. Hochman · JAMA · 2001 · 684 citations · Full text
Medicine, Cardiology, Surgery +10
The Standardized Normal Ivy Bleeding Time and Its Prolongation by Aspirin
C. Harold Mielke, Marc Kaneshiro, Ian A. Maher et al. · Blood · 1969 · 664 citations · Full text
Activated platelets signal chemokine synthesis by human monocytes.
Andrew S. Weyrich, M R Elstad, R P McEver et al. · Journal of Clinical Investigation · 1996 · 600 citations · Full text